Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Genepoint Biological Technology

Explore full profile

Genepoint Biological Technology is a healthcare Company

ChinaFounded 2015Biotech & Life Sciences
Valuation $100–250M Last recorded · 2023
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Genepoint Biological Technology and the history behind them.

About Genepoint Biological Technology

Genepoint Biological Technology, established in Shanghai in July 2015, operates as a specialized provider of automated, intelligent solutions for the low-temperature preservation of biological resources. The company was founded by Chen Zhehua, who holds an MBA from Tongji University and previously served as the China Business Development Manager at Air Products (China) Investment Co., Ltd., where he was instrumental in developing the company's medical business sector. Genepoint has secured significant venture capital, with its latest Series D funding round in January 2023 raising nearly $29.5 million, led by investors such as Shanghai Guofang Private Equity Fund Management, LYFE Capital, and Huajin Capital.

The firm's business model is centered on the in-house research, development, and manufacturing of advanced cryogenic robotic systems and automated ultra-low temperature storage solutions. Its client base includes top-tier gene banks, research universities, hospitals, and biopharmaceutical facilities, primarily across Asia. Genepoint generates revenue through the sale of its specialized equipment and consumables. The company has established a strong market presence, underscored by its portfolio of over 220 patents and a research and development team that constitutes more than 32% of its workforce.

Genepoint's product suite offers comprehensive solutions for the entire bio-sample storage management process. Key offerings include the 'Hatch' series, a fully automated cryogenic robot and repository system for fast, intelligent retrieval of samples in liquid nitrogen environments. Its 'Hatch-Lite' model was recognized with the ISBER Outstanding New Product Award in 2019, a first for an Asian company in this category. Another core product, the 'Snorkel' Automated Sample Repository System, integrates advanced refrigeration technology and user-friendly intelligent interaction for efficient sample management. The 'Crest' line consists of intelligent cryogenic storage systems that maintain temperatures below -180°C using advanced vacuum extraction and insulation technology. To complement its automated systems, the company provides a range of consumables under the 'Sinfo' brand, including co-molded cryotubes designed for both automated and manual applications.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2015
Headquarters
China
Employees
4
Open positions
None listed
Dealroom signal
30.8/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus
b2b

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Jan 2023 $30M $118M Guofang Capital · LYFE Capital · Huajin Capital · Guosheng Capital ↗
SERIES COther financing Feb 2022 $19M $76M NLVC ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Genepoint Biological Technology website traffic

Latest recorded traffic for Genepoint Biological Technology is 540 monthly website visits, up 1700% over the last three months. Genepoint Biological Technology's team grew 0% over the past year.

Latest monthly visits540 3-month web change+1700% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later7 investors entered at this stage

  • NLVC
  • Guofang Capital
  • LYFE Capital
  • Huajin Capital
  • Guosheng Capital
  • Deyi Capital
  • Guolian Capital
Employees 4 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Genepoint Biological Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Genepoint Biological Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.